A citation-based method for searching scientific literature

Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Times Cited: 493







List of shared articles



Times cited


Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes.
Xiaoya Sun, Ziqiang Cao, Yuanyuan Ma, Yimin Shao, Junqing Zhang, Geheng Yuan, Xiaohui Guo. Food Funct 2021
1

Blood glucose levels and bodyweight change after dapagliflozin administration.
Hyunah Kim, Seung-Hwan Lee, Hyunyong Lee, Hyeon Woo Yim, Jae-Hyoung Cho, Kun-Ho Yoon, Hun-Sung Kim. J Diabetes Investig 2021
0

Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
SooJeong Ko, HyungMin Kim, Jiwon Shinn, Sun-Ju Byeon, Jeong-Hee Choi, Hun-Sung Kim. J Clin Pharm Ther 2021
0


Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Gilson C Fernandes, Amanda Fernandes, Rhanderson Cardoso, Jorge Penalver, Leonardo Knijnik, Raul D Mitrani, Robert J Myerburg, Jeffrey J Goldberger. Heart Rhythm 2021
1

Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM.
Aml Mohamed Nada, Mariam Adel Younan. Ther Adv Endocrinol Metab 2021
0

Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults.
Mohamad Sirri Tarazi, Samir Touhamy, Beverly G Tchang, Alpana P Shukla. Expert Opin Pharmacother 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
0

Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
Mehmet Kanbay, Laura Tapoi, Carina Ureche, Cem Tanriover, Enes Cevik, Atalay Demiray, Baris Afsar, David Z I Cherney, Adrian Covic. Int Urol Nephrol 2021
0

The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Rosalie A Scholtes, Daniël H van Raalte, Ricardo Correa-Rotter, Robert D Toto, Hiddo J L Heerspink, Valerie Cain, C David Sjöström, Peter Sartipy, Bergur V Stefánsson. Diabetes Obes Metab 2020
4



Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2020
7

Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice.
Hyunah Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim. J Clin Pharm Ther 2020
1




SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
Angus Gill, Stephen P Gray, Karin A Jandeleit-Dahm, Anna M D Watson. Curr Diabetes Rev 2019
1

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Hiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, Melissa K Hallow, Valerie A Cain, Peter Rossing, Bergur V Stefansson, Peter Sartipy. Diabetes Obes Metab 2019
9

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Takayoshi Suga, Osamu Kikuchi, Masaki Kobayashi, Sho Matsui, Hiromi Yokota-Hashimoto, Eri Wada, Daisuke Kohno, Tsutomu Sasaki, Kazusane Takeuchi, Satoru Kakizaki,[...]. Mol Metab 2019
37

Heart Failure in Type 2 Diabetes Mellitus.
Helena C Kenny, E Dale Abel. Circ Res 2019
119

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, David Nathanson, Jan W Eriksson. Diabetes Obes Metab 2019
38

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
Stuart J McGurnaghan, Liam Brierley, Thomas M Caparrotta, Paul M McKeigue, Luke A K Blackbourn, Sarah H Wild, Graham P Leese, Rory J McCrimmon, John A McKnight, Ewan R Pearson,[...]. Diabetologia 2019
11


Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Xiaoling Cai, Lizheng Shi, Wenjia Yang, Shuyan Gu, Yingyao Chen, Lin Nie, Linong Ji. J Med Econ 2019
7

Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
Ann M McNeill, Glenn Davies, Eliza Kruger, Stacey Kowal, Tim Reason, Flavia Ejzykowicz, Hakima Hannachi, Nilo Cater, Euan McLeod. Diabetes Ther 2019
7

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
73

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
46


Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
Sang Hyun Park, Young Ju Choi, Eun Jung Rhee, Kab Bum Huh. Endocrinol Metab (Seoul) 2019
0

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
30

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal. Indian J Endocrinol Metab 2019
5

SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Jyotsana Pandey, Akhilesh K Tamrakar. Expert Opin Ther Pat 2019
8

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4


Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes.
Habib Yaribeygi, Stephen L Atkin, Amirhossein Sahebkar. Diabetes Metab Syndr 2019
5


Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Humberto Reyes-Pardo, Rocío Bautista, Hilda Vargas-Robles, Amelia Rios, Daniel Sánchez, Bruno Escalante. BMC Nephrol 2019
4